280 related articles for article (PubMed ID: 25877052)
21. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T
Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
[TBL] [Abstract][Full Text] [Related]
22. [Neuropathology of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy].
Kanda T
Brain Nerve; 2015 Jul; 67(7):891-901. PubMed ID: 26160817
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
[TBL] [Abstract][Full Text] [Related]
24. Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab.
Valenzuela RM; Pula JH; Garwacki D; Cotter J; Kattah JC
J Neurol Sci; 2014 May; 340(1-2):109-11. PubMed ID: 24680560
[TBL] [Abstract][Full Text] [Related]
25. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
Krämer J; Tenberge JG; Kleiter I; Gaissmaier W; Ruck T; Heesen C; Meuth SG
PLoS One; 2017; 12(4):e0174858. PubMed ID: 28406921
[TBL] [Abstract][Full Text] [Related]
26. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
Havla J; Berthele A; Kümpfel T; Krumbholz M; Jochim A; Kronsbein H; Ryschkewitsch C; Jensen P; Lippmann K; Hemmer B; Major E; Hohlfeld R
Mult Scler; 2013 Aug; 19(9):1213-5. PubMed ID: 23124790
[TBL] [Abstract][Full Text] [Related]
27. Radiological abnormalities in progressive multifocal leukoencephalopathy: Identifying typical and atypical imaging patterns for early diagnosis and differential considerations.
Soni N; Ora M; Mangla R; Singh R; Ellika S; Agarwal A; Meyers SP; Bathla G
Mult Scler Relat Disord; 2023 Sep; 77():104830. PubMed ID: 37418930
[TBL] [Abstract][Full Text] [Related]
28. In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection.
Martin-Blondel G; Bauer J; Cuvinciuc V; Uro-Coste E; Debard A; Massip P; Delisle MB; Lassmann H; Marchou B; Mars LT; Liblau RS
Neurology; 2013 Sep; 81(11):964-70. PubMed ID: 23935178
[TBL] [Abstract][Full Text] [Related]
29. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
Hunt D; Giovannoni G
Pract Neurol; 2012 Feb; 12(1):25-35. PubMed ID: 22258169
[TBL] [Abstract][Full Text] [Related]
30. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
Tur C; Tintoré M; Vidal-Jordana A; Castilló J; Galán I; Río J; Arrambide G; Comabella M; Arévalo MJ; Horno R; Vicente MJ; Caminero A; Nos C; Sastre-Garriga J; Montalban X
Mult Scler; 2012 Aug; 18(8):1193-6. PubMed ID: 22383232
[TBL] [Abstract][Full Text] [Related]
31. Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.
Wattjes MP; Wijburg MT; van Eijk J; Frequin S; Uitdehaag BMJ; Barkhof F; Warnke C; Killestein J;
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):535-541. PubMed ID: 29142146
[TBL] [Abstract][Full Text] [Related]
32. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
[TBL] [Abstract][Full Text] [Related]
33. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.
van Rossum JA; Vennegoor A; Balk L; Uitdehaag BM; Polman CH; Killestein J
Mult Scler; 2014 Jan; 20(1):108-11. PubMed ID: 23828867
[TBL] [Abstract][Full Text] [Related]
34. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
[TBL] [Abstract][Full Text] [Related]
35. Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report.
Mickeviciene D; Baltusiene A; Afanasjeva B; Afanasjevas D; Gleizniene R; Rastenyte D; Berger JR
BMC Neurol; 2022 Aug; 22(1):306. PubMed ID: 35986243
[TBL] [Abstract][Full Text] [Related]
36. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
[TBL] [Abstract][Full Text] [Related]
37. [[Natalizumab therapy, 2013].
Karácsony M; Bencsik K; Vécsei L
Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
[TBL] [Abstract][Full Text] [Related]
38. Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy.
Calvi A; De Riz M; Pietroboni AM; Ghezzi L; Maltese V; Arighi A; Fumagalli GG; Jacini F; Donelli C; Comi G; Galimberti D; Scarpini E
Immunotherapy; 2014; 6(1):23-8. PubMed ID: 24341880
[TBL] [Abstract][Full Text] [Related]
39. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
[TBL] [Abstract][Full Text] [Related]
40. Natalizumab-Related Progressive Multifocal Leukoencephalopathy-Immune Reconstitution Inflammatory Syndrome: A Case Report Highlighting Clinical and MRI Features.
Purohit B; Ganewatte E; Kollias SS
Malays J Med Sci; 2016 Sep; 23(5):91-95. PubMed ID: 27904430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
